Episode 4. Hepatitis C with Dr Ferry Rusli
In this episode I have a conversation with hepatologist and gastroenterologist Dr Ferry Rusli in a four-part series on liver disease where we explore chronic hepatitis C, its population reservoirs in Australia and approaches to treatment. In particular, Ferry points out - · The need to increase our effectiveness at treating hepatitis C in at risk populations.
In this episode I have a conversation with hepatologist and gastroenterologist Dr Ferry Rusli in a four-part series on liver disease where we explore chronic hepatitis C, its population reservoirs in Australia and approaches to treatment. In particular, Ferry points out - · The need to increase our effectiveness at treating hepatitis C in at risk populations.
In this episode I have a conversation with hepatologist and gastroenterologist Dr Ferry Rusli in a four-part series on liver disease where we explore chronic hepatitis C, its population reservoirs in Australia and approaches to treatment.
In particular, Ferry points out –
· The need to increase our effectiveness at treating hepatitis C in at risk populations (e.g. prison population)
· Discusses the impressive breakthrough with new antiviral therapies and their effectiveness in curing hepatitis C
· Surveillance for hepatocellular carcinoma
I really hope you find this conversation as interesting as I did.
Useful references include -
To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au
Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.
Episode 3. Hepatitis B with Dr Ferry Rusli
In this episode I talk with experienced gastroenterologist and hepatologist Dr Ferry Rusli on the subject of hepatitis B in a four-part series on liver disease. Ferry discusses - · the prevalence of hepatitis B in the Asia Pacific region · the long-term complications and consequences of hepatitis B · treatment options including pharmacological therapies which are currently falling short of the national target for patients receiving treatment.
In this episode I talk with experienced gastroenterologist and hepatologist Dr Ferry Rusli on the subject of hepatitis B in a four-part series on liver disease. Ferry discusses -
· the prevalence of hepatitis B in the Asia Pacific region
· the long-term complications and consequences of hepatitis B
· treatment options including pharmacological therapies which are currently falling short of the national target for patients receiving treatment.
This conversation provides a great introduction to current approaches to hepatitis B management. I hope you enjoy the conversation.
Useful reference are -
To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au
Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.
Episode 2. Non-Alcoholic Fatty Liver Disease with Dr Ferry Rusli
In this episode I am joined by Dr Ferry Rusli, an experienced gastroenterologist and hepatologist to discuss non-alcoholic fatty liver disease in a four-part series on hepatology. Ferry discusses the relevance of non-alcoholic fatty liver disease to the metabolic syndrome and some key management points, in particular focussing on controlling body mass index. There is much to learn from this conversation with Ferry, I hope you enjoy the conversation.
In this episode I am joined by Dr Ferry Rusli, an experienced gastroenterologist and hepatologist to discuss non-alcoholic fatty liver disease in a four-part series on hepatology.
Ferry discusses –
· the prevalence of non-alcoholic fatty liver disease (NAFLD) as it applies to the Australian population
· non-alcoholic steatohepatitis (NASH)
· cirrhosis, hepatocellular carcinoma and liver failure as sequela of unmanaged NASH
Ferry discusses the relevance of non-alcoholic fatty liver disease to the metabolic syndrome and some key management points, in particular focussing on controlling body mass index. There is much to learn from this conversation with Ferry, I hope you enjoy the conversation.
Useful references include -
www.hepvic.org.au/fattyliverdisease
To be a guest on the show or provide some feedback, I’d love to hear from you: manager@gihealth.com.au
Dr Luke Crantock MBBS, FRACP, is a gastroenterologist in practice for over 25 years. He is the founder of The Centre for GI Health, based in Melbourne Australia and is passionate about educating General Practitioners and patients on disease prevention and how to manage and improve their digestive health.